These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chromatin engineering offers an opportunity to advance epigenetic cancer therapy. Baskin NL; Haynes KA Nat Struct Mol Biol; 2019 Oct; 26(10):842-845. PubMed ID: 31582843 [No Abstract] [Full Text] [Related]
3. Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer. Luan J; Chu Z; Chandra J; Zhang P Curr Protein Pept Sci; 2016; 17(5):455-62. PubMed ID: 26796303 [TBL] [Abstract][Full Text] [Related]
4. Editorial (Thematic Issue: Chromatin Structure Regulating Proteins: Biology and Therapeutic Potential for Cancer). Zhang P; Pollock RE Curr Protein Pept Sci; 2016; 17(5):400. PubMed ID: 26796070 [No Abstract] [Full Text] [Related]
5. Translating epigenetics into an anticancer drug pipeline for solid tumors. Roukos DH Expert Rev Med Devices; 2011 Jul; 8(4):409-13. PubMed ID: 21728725 [No Abstract] [Full Text] [Related]
6. Epigenetic opportunities and challenges in cancer. Best JD; Carey N Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050 [TBL] [Abstract][Full Text] [Related]
7. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Cai SF; Chen CW; Armstrong SA Mol Cell; 2015 Nov; 60(4):561-70. PubMed ID: 26590715 [TBL] [Abstract][Full Text] [Related]
8. Epigenetics: Novel Therapeutics Targeting Epigenetics. Conway SJ; Woster PM; Greenlee WJ; Georg G; Wang S J Med Chem; 2016 Feb; 59(4):1247-8. PubMed ID: 26824165 [No Abstract] [Full Text] [Related]
9. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. Verma SK; Knight SD Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271 [TBL] [Abstract][Full Text] [Related]
10. Chromatin-modifying agents in anti-cancer therapy. Seidel C; Florean C; Schnekenburger M; Dicato M; Diederich M Biochimie; 2012 Nov; 94(11):2264-79. PubMed ID: 22627380 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic Regulation and Drug Discovery for Cancer Therapy. Yu B; Ouyang L Curr Top Med Chem; 2019; 19(12):971. PubMed ID: 31486748 [No Abstract] [Full Text] [Related]
12. New hopes in the fight against cancer: a special issue on targeted anti-cancer drug discovery and cell signaling. Cheng X Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):1-2. PubMed ID: 26578705 [No Abstract] [Full Text] [Related]
13. What is the potential of epigenetics in drug development? Lundstrom K Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357 [No Abstract] [Full Text] [Related]
14. Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy. Li J; Hao D; Wang L; Wang H; Wang Y; Zhao Z; Li P; Deng C; Di LJ Sci Rep; 2017 Jun; 7(1):4035. PubMed ID: 28642588 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic drugs against cancer: an evolving landscape. Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708 [TBL] [Abstract][Full Text] [Related]
16. Genetic discoveries propagate new epigenetic drugs. Garber K J Natl Cancer Inst; 2012 Feb; 104(3):174-6. PubMed ID: 22271768 [No Abstract] [Full Text] [Related]
17. Using Chemical Epigenetics to Target Cancer. Wimalasena VK; Wang T; Sigua LH; Durbin AD; Qi J Mol Cell; 2020 Jun; 78(6):1086-1095. PubMed ID: 32407673 [TBL] [Abstract][Full Text] [Related]
18. Chemical inhibitors make their RNA epigenetic mark. Cully M Nat Rev Drug Discov; 2019 Nov; 18(12):892-894. PubMed ID: 31780844 [No Abstract] [Full Text] [Related]
19. The Dual Roles of NRF2 in Cancer. Menegon S; Columbano A; Giordano S Trends Mol Med; 2016 Jul; 22(7):578-593. PubMed ID: 27263465 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]